IMMUNITYBIO INC (IBRX) — insider trading
Health Care · NASDAQ
IMMUNITYBIO INC (IBRX) has 30 reported SEC Form 4 insider transactions in our data, including 6 open-market sales among the most recent 30 (latest 2026-07-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Cohen Cheryl | Director | Option exercise / conversion (derivative) | 55,979 | $0.00 | $0 | Form 4 |
| 2026-07-02 | Cohen Cheryl | Director | Open-market sale | 131,210 | $9.50 | $1.25M | Form 4 |
| 2026-07-02 | Cohen Cheryl | Director | Option exercise / conversion | 55,979 | $2.98 | $166.8K | Form 4 |
| 2026-07-01 | Selecky Christobel | Director | Option exercise / conversion (derivative) | 124,414 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Selecky Christobel | Director | Option exercise / conversion (derivative) | 35,064 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Selecky Christobel | Director | Open-market sale | 159,478 | $9.02 | $1.44M | Form 4 |
| 2026-07-01 | Selecky Christobel | Director | Option exercise / conversion | 124,414 | $2.99 | $372.0K | Form 4 |
| 2026-07-01 | Selecky Christobel | Director | Option exercise / conversion | 35,064 | $2.98 | $104.5K | Form 4 |
| 2026-06-30 | Selecky Christobel | Director | Option exercise / conversion (derivative) | 300 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Selecky Christobel | Director | Option exercise / conversion (derivative) | 700 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Selecky Christobel | Director | Open-market sale | 1,000 | $9.00 | $9.0K | Form 4 |
| 2026-06-30 | Selecky Christobel | Director | Option exercise / conversion | 300 | $2.99 | $897 | Form 4 |
| 2026-06-30 | Selecky Christobel | Director | Option exercise / conversion | 700 | $2.98 | $2.1K | Form 4 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise / conversion (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise / conversion (derivative) | 33,549 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise / conversion (derivative) | 32,173 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Selecky Christobel | Director | Open-market sale | 95,722 | $9.01 | $862.2K | Form 4 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise / conversion | 30,000 | $2.84 | $85.2K | Form 4 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise / conversion | 33,549 | $2.99 | $100.3K | Form 4 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise / conversion | 32,173 | $2.98 | $95.9K | Form 4 |
| 2026-06-24 | Simon Barry J. | Director | Open-market sale | 25,000 | $7.88 | $196.9K | Form 4 |
| 2026-06-09 | Selecky Christobel | Director | Grant / award / vesting (derivative) | 65,600 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Cohen Cheryl | Director | Grant / award / vesting (derivative) | 65,600 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Clark Wesley | Director | Grant / award / vesting (derivative) | 65,600 | $0.00 | $0 | Form 4 |
| 2026-06-09 | MAXWELL LINDA | Director | Grant / award / vesting (derivative) | 65,600 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Wendel Bruce | Director | Grant / award / vesting (derivative) | 65,600 | $0.00 | $0 | Form 4 |
| 2026-06-09 | BLASZYK MICHAEL D | Director | Grant / award / vesting (derivative) | 65,600 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Simon Barry J. | Director | Open-market sale | 23,033 | $7.18 | $165.3K | Form 4 |
| 2026-03-31 | SOON-SHIONG PATRICK; CALIFORNIA CAPITAL EQUITY, LLC; Cambridge Equities, LP; MP 13 Ventures, LLC; Nant Capital, LLC | Director, Officer (See remarks), 10% owner | Conversion of derivative (derivative) | — | $0.00 | — | Form 4 |
| 2026-03-31 | SOON-SHIONG PATRICK; CALIFORNIA CAPITAL EQUITY, LLC; Cambridge Equities, LP; MP 13 Ventures, LLC; Nant Capital, LLC | Director, Officer (See remarks), 10% owner | Conversion of derivative | 4,606,596 | $5.43 | $25.00M | Form 4 |
Ask the chat about IBRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: IMMUNITYBIO INC (IBRX).
Last updated 2026-07-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.